by PEPID Newsroom | Mar 28, 2019 | Alerts
Influenza activity, particularly caused by the A(H3N2) virus, remains elevated across the US. The CDC has released a health advisory, reminding clinicians to keep influenza top of mind when diagnosing patients with respiratory illness. The report contains several...
by PEPID Newsroom | Oct 31, 2018 | Alerts
Yesterday the U.S. Food and Drug Administration approved Xofluza (balorxavir marhboxil), a new influenza treatment for acute uncomplicated influenza in people age 12 and older who have been symptomatic for no more than 2 days. This new drug, developed by Genentech,...
